Skip to content
Open access · CC-BY via OpenAlex

Peptide-based approaches to directly target alpha-synuclein in Parkinson’s disease

Scott G. Allen, Richard M. Meade, Lucy L. White Stenner, Jody M. Mason

Molecular Neurodegeneration · 2023 · ▲ 35 citations

Abstract

Peptides and their mimetics are increasingly recognised as drug-like molecules, particularly for intracellular protein-protein interactions too large for inhibition by small molecules, and inaccessible to larger biologics. In the past two decades, evidence associating the misfolding and aggregation of alpha-synuclein strongly implicates this protein in disease onset and progression of Parkinson's disease and related synucleinopathies. The subsequent formation of toxic, intracellular, Lewy body deposits, in which alpha-synuclein is a major component, is a key diagnostic hallmark of the disease. To reach their therapeutic site of action, peptides must both cross the blood-brain barrier and enter dopaminergic neurons to prevent the formation of these intracellular inclusions. In this review, we describe and summarise the current efforts made in the development of peptides and their mimetics to directly engage with alpha-synuclein with the intention of modulating aggregation, and importantly, toxicity. This is a rapidly expanding field with great socioeconomic impact; these molecules harbour significant promise as therapeutics, or as early biomarkers during prodromal disease stages, or both. As these are age-dependent conditions, an increasing global life expectancy means disease prevalence is rising. No current treatments exist to either prevent or slow disease progression. It is therefore crucial that drugs are developed for these conditions before health care and social care capacities become overrun.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1186/s13024-023-00675-8
Canonical
link ↗
Fetched
2026-10-21 MST

Cite this

APA
Allen, S.G., Meade, R.M., Stenner, L.L.W., &amp; Mason, J.M. (2023). Peptide-based approaches to directly target alpha-synuclein in Parkinson’s disease. <em>Molecular Neurodegeneration</em>. https://doi.org/10.1186/s13024-023-00675-8
Vancouver
Allen SG, Meade RM, Stenner LLW, Mason JM. Peptide-based approaches to directly target alpha-synuclein in Parkinson’s disease. Molecular Neurodegeneration. 2023. doi:10.1186/s13024-023-00675-8.
BibTeX
@article{scott2023Peptid, title = {Peptide-based approaches to directly target alpha-synuclein in Parkinson’s disease}, author = {Scott G. Allen and Richard M. Meade and Lucy L. White Stenner and Jody M. Mason}, journal = {Molecular Neurodegeneration}, year = {2023}, doi = {10.1186/s13024-023-00675-8}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings